Merck immunotherapy fails to improve survival in head and neck cancer - Reuters

STAT

Merck immunotherapy fails to improve survival in head and neck cancer Reuters (Reuters) - Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial. The drug, which blocks a ... Merck: Keytruda trial comes up short in head and neck cancer, but FDA approval staysSTAT (pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous ...Business Wire (press release) Merck hit with another late-stage setback on checkpoint star KeytrudaEndpoints News all 4 news articles »

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2uRMGFA
via IFTTT